Endowment Wealth Management Inc. Has $106,000 Holdings in Haleon plc (NYSE:HLN)

Endowment Wealth Management Inc. raised its holdings in shares of Haleon plc (NYSE:HLN) by 9.9% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 12,867 shares of the company’s stock after purchasing an additional 1,161 shares during the period. Endowment Wealth Management Inc.’s holdings in Haleon were worth $106,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors also recently added to or reduced their stakes in the business. Janney Montgomery Scott LLC raised its position in shares of Haleon by 182.3% in the 1st quarter. Janney Montgomery Scott LLC now owns 438,833 shares of the company’s stock valued at $3,726,000 after acquiring an additional 283,410 shares during the period. Capstone Investment Advisors LLC acquired a new stake in Haleon during the 1st quarter worth approximately $1,969,000. Wellington Management Group LLP raised its holdings in Haleon by 164.6% during the 4th quarter. Wellington Management Group LLP now owns 13,542,346 shares of the company’s stock worth $111,454,000 after buying an additional 8,423,475 shares during the period. Patrick M Sweeney & Associates Inc. acquired a new stake in Haleon during the 4th quarter worth approximately $1,083,000. Finally, Douglas Lane & Associates LLC raised its holdings in Haleon by 2.1% during the 1st quarter. Douglas Lane & Associates LLC now owns 8,401,876 shares of the company’s stock worth $71,332,000 after buying an additional 175,082 shares during the period. 6.67% of the stock is currently owned by institutional investors and hedge funds.

Haleon Trading Up 0.9 %

Shares of Haleon stock opened at $10.18 on Tuesday. The business has a fifty day simple moving average of $9.23 and a two-hundred day simple moving average of $8.67. Haleon plc has a 1 year low of $7.70 and a 1 year high of $10.23. The company has a market capitalization of $46.48 billion, a price-to-earnings ratio of 33.93, a P/E/G ratio of 2.99 and a beta of 0.24. The company has a debt-to-equity ratio of 0.44, a current ratio of 0.84 and a quick ratio of 0.58.

Haleon (NYSE:HLN) last announced its quarterly earnings results on Thursday, August 1st. The company reported $0.08 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.09 by ($0.01). Haleon had a net margin of 9.71% and a return on equity of 13.15%. The business had revenue of $3.50 billion for the quarter, compared to analyst estimates of $3.55 billion. During the same period in the prior year, the business earned $0.08 EPS. Research analysts forecast that Haleon plc will post 0.46 EPS for the current year.

Haleon Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Thursday, September 19th. Stockholders of record on Friday, August 16th will be issued a dividend of $0.0514 per share. This represents a dividend yield of 1.6%. The ex-dividend date of this dividend is Friday, August 16th. Haleon’s dividend payout ratio is currently 33.33%.

Analysts Set New Price Targets

HLN has been the subject of several analyst reports. The Goldman Sachs Group cut shares of Haleon from a “buy” rating to a “neutral” rating in a research note on Tuesday, August 6th. Berenberg Bank initiated coverage on shares of Haleon in a research note on Tuesday, August 6th. They issued a “buy” rating for the company. One research analyst has rated the stock with a hold rating and four have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy”.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.